Revance TherapeuticsRVNC
About: Revance Therapeutics Inc is a biotechnology company focused on aesthetic and therapeutic offerings, including its neuromodulator product, DaxibotulinumtoxinA for Injection. The company has launched a prestige aesthetics portfolio, which includes the RHA Collection of dermal fillers and the HintMD platform. Its main products include DaxibotulinumtoxinA for Injection and DaxibotulinumtoxinA for Injection Aesthetics. The operating business segments are the Product and the Service Segment. The Products segment generates maximum revenue and is engaged in the research and development of aesthetic and therapeutic products.
Employees: 597
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
103% more call options, than puts
Call options by funds: $1.57M | Put options by funds: $775K
50% more repeat investments, than reductions
Existing positions increased: 63 | Existing positions reduced: 42
0% more funds holding in top 10
Funds holding in top 10: 2 [Q1] → 2 (+0) [Q2]
3.2% less ownership
Funds ownership: 82.06% [Q1] → 78.86% (-3.2%) [Q2]
8% less funds holding
Funds holding: 186 [Q1] → 172 (-14) [Q2]
34% less first-time investments, than exits
New positions opened: 27 | Existing positions closed: 41
50% less capital invested
Capital invested by funds: $422M [Q1] → $212M (-$211M) [Q2]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
2 analyst ratings
HC Wainwright & Co. Douglas Tsao 53% 1-year accuracy 54 / 102 met price target | 60%upside $6.60 | Neutral Reiterated | 8 Nov 2024 |
Barclays Balaji Prasad 52% 1-year accuracy 17 / 33 met price target | 69%upside $7 | Equal-Weight Downgraded | 13 Sept 2024 |
Financial journalist opinion
Based on 35 articles about RVNC published over the past 30 days
